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 25 
ABSTRACT 26 
 27 
Molecular diagnosis of congenital toxoplasmosis or disseminated toxoplasmosis is mainly 28 
based on PCR. The repeated DNA element rep529 has become the main DNA target used in 29 
most, whether laboratory-developed or commercial, PCR methods. In this multicenter study, 30 
we evaluated the Toxoplasma ELITe MGB® (Elitech®) commercial kit, by comparison with 31 
three reference quantitative PCR assays (RA) used in routine in three proficient laboratories 32 
of the French National Reference Center for Toxoplasmosis network, using Toxoplasma 33 
calibrated suspensions diluted to obtain a range of concentrations from 0.1 to 10,000 34 
parasites/mL. These suspensions were extracted either with the DNA extraction kit 35 
(EXTRAblood®, Elitech®) recommended by the manufacturer or the QIAamp DNA-minikit 36 
(Qiagen). The Toxoplasma ELITe MGB® assay was also evaluated on a panel of 128 clinical 37 
samples, including 56 amniotic fluid, 55 placenta, and various other samples, of which 95 38 
originated from patients with proven toxoplasmosis. The ELITe MGB assay amplified less 39 
frequently low-concentration replicates (<10 parasites/mL) of calibrated suspensions, than 40 
the RA of 2/3 laboratories. Additionally, the combination EXTRAblood® / Toxoplasma ELITe 41 
MGB® yielded poorer sensitivity than the combination QIAmp DNA-minikit/ ELITe MGB®  for 42 
low parasite concentrations (p<0.001 for 1 parasite/mL). On clinical samples, the sensitivity 43 
and the specificity of the commercial assay were 89% and 100%, respectively. The sensitivity 44 
ranged from 79% to 100% with placenta and amniotic fluid samples, respectively. Overall, 45 
this study shows that the Toxoplasma ELITe MGB® assay is suitable for the diagnosis of 46 
toxoplasmosis from non-cell-rich or non-hemoglobin-rich samples, and that the 47 
EXTRAblood® kit is not optimal.  48 
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INTRODUCTION 49 
Toxoplasmosis is a worldwide parasitic disease due to the intracellular coccidian parasite 50 
Toxoplasma gondii. Molecular diagnosis is an essential tool for the diagnosis of congenital 51 
toxoplasmosis, as well as of acute disease in immunocompromised patients with primary 52 
infection or reactivation of past infection (1). Prenatal diagnosis of congenital toxoplasmosis 53 
relies on Toxoplasma DNA detection in amniotic fluid (AF), and has been largely evaluated in 54 
field studies, particularly in French series, as a national prevention program implemented in 55 
1992 requires a monthly serologic follow-up of seronegative pregnant women and 56 
recommends the realization of amniocentesis when a primary infection is documented. In 57 
France, 21 University Hospitals have a ministerial agreement for the prenatal diagnosis of 58 
congenital toxoplasmosis. Since several years now, all of them have moved for the use of 59 
real-time PCR (rtPCR) methods targeting the repeated DNA element rep529 (GenBank 60 
accession number AF146527), as the sensitivity provided using this DNA target has proved 61 
higher than that of the formerly used B1 gene in most studies (2-5). About three quarters of 62 
these reference laboratories still use 'in-house' or laboratory-developed rtPCR techniques 63 
which have been evaluated in clinical studies; but there is an increasing trend to use 64 
commercial assays, which, in spite of being more expensive, are easier to use and allow a 65 
better quality management than the former. The manufacturers of these kits announce a 66 
sensitivity threshold, but the performance of these assays may be altered by the tested 67 
sample type or the DNA extraction method used. Indeed, Toxoplasma may be searched not 68 
only for the prenatal diagnosis of congenital toxoplasmosis, but also in 69 
immunocompromised patients in other sample types, such as blood, broncho-alveolar 70 
lavage fluid, cerebrospinal fluid (CSF), aqueous humor (AH) or various biopsies (6). In view of 71 
the globally excellent performances of 'in-house' methods in proficient diagnostic centers 72 
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(7), the evaluation of the analytical and clinical performances of commercial kits is absolutely 73 
needed to ensure the quality of results in routine use. Moreover, some commercial assays 74 
are validated for Toxoplasma detection in AF, but not in other sample types. In this 75 
multicenter study, we evaluated the performances of the Toxoplasma ELITe MGB® kit 76 
(Elitech®, Puteaux, France), a rep529-targeting assay, using serial dilutions of calibrated 77 
Toxoplasma suspensions in AF, and clinical samples including AF, placenta and various other 78 
types of samples.  79 
 80 
MATERIALS & METHODS 81 
Participating centers 82 
The three participating centers (University Hospitals of Paris-Cochin, Rennes and Grenoble, 83 
France) are part of the Molecular Biology workgroup of the French National Reference 84 
Center for Toxoplasmosis (NRCT: http://cnrtoxoplasmose.chu-reims.fr/?lang=en), and have a 85 
ministerial agreement for the prenatal diagnosis of toxoplasmosis. They participate to 86 
national external quality controls on a regular basis with satisfactory results.  87 
 88 
Samples 89 
Calibrated Toxoplasma suspensions 90 
The three participating centers used a calibrated Toxoplasma (type II) suspension produced 91 
by the Molecular Biology workgroup of the NRCT (University Hospital of Montpellier)(8). 92 
DNA was previously extracted from the suspension in each center using their routine 93 
method for molecular diagnosis (here, QIAamp DNA mini-kit®, Qiagen, Les Ulis, France). The 94 
three labs compared the sensitivity of detection of serial dilutions (from 10,000 95 
tachyzoites/mL to 0.1/mL) after amplification using their own in-house PCR method (so-96 
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called reference assay (RAs, Table 1) and the Toxoplasma ELITe MGB® kit, following the 97 
manufacturer’s instructions. All dilution points were amplified in triplicate or quadruplicate. 98 
Another batch of calibrated suspension was extracted in parallel, using either the manual 99 
extraction device recommended by the manufacturer, i.e. EXTRAblood® (Elitech), or with the 100 
QIAamp DNA mini-kit®. In this experiment, the internal control was added at the time of 101 
extraction, following the manufacturer’s instructions (see below). 102 
Additionally, one center also evaluated a batch of 10 samples of external quality controls 103 
(EQC) from QCMD® (2014). This QC batch (TGDNA 14) consisted of 5 vials of lyophilized 104 
amniotic fluid samples spiked with various concentrations of T. gondii or unspiked 105 
(negative), and 5 vials of lyophilized plasma samples spiked with various concentrations of T. 106 
gondii or unspiked (negative), and was extracted using EXTRAblood® (Elitech). 107 
 108 
Clinical samples 109 
This part of the work used stored DNA from clinical samples obtained during routine 110 
molecular diagnosis (2005-2015). The three reference laboratories selected Toxoplasma-111 
positive and -negative DNA preserved at -20°C or -80°C following routine molecular diagnosis 112 
(9). Thanks to the French prevention program for congenital toxoplasmosis, reference 113 
centers have a collection of samples (mainly AF and placenta samples) from patients with 114 
confirmed diagnosis. As already evaluated in previous studies, long-term storage of DNA at -115 
20°C or below does not alter the result of Toxoplasma real-time PCR (3, 9), thus allowing the 116 
use of collections for diagnostic evaluations. Placenta and AF DNA samples from fetuses with 117 
suspected congenital toxoplasmosis were classified as true-positive or true-negative on the 118 
basis of the newborn serological follow-up (detection of specific IgM or IgA, and comparison 119 
of mother and newborn antibody profiles by western-blotting during a one-year follow-up), 120 
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so that the diagnosis could be definitely confirmed or ruled out, as previously described (10-121 
13). The Elitech assay was certified CE-IVD in 2013 and validated for amniotic fluid samples 122 
and whole blood, thus we considered that placenta samples were comparable to blood 123 
samples. Other samples were collected from patients with retinochoroiditis or from 124 
immunocompromised patients, for whom the clinical diagnosis was recorded (disseminated, 125 
cerebral, or toxoplasmosis excluded). Overall, 128 DNA samples were included: 55 isolated 126 
from placentas, 56 from AF, 4 from AH, 6 leukocyte pellets isolated from buffy-coats, 2 from 127 
biopsies, and 5 from CSF. Of these, 33 samples were classified as PCR-negative and 95 as 128 
PCR-positive, according to serological and clinical follow-up of patients. 129 
 130 
Molecular techniques 131 
DNA extraction of clinical specimens 132 
Clinical specimens were processed in the setting of routine diagnosis. After appropriate pre-133 
analytical steps (centrifugation of fluids, buffy-coat, pre-digestion of placenta or biopsies 134 
with proteinase K), 200 µL of clinical samples were extracted using the QIAamp DNA mini-135 
kit® according to the manufacturer’s instructions, and eluted in 100 µL (all three centers 136 
used the same technique for routine diagnosis).  137 
DNA extraction of Toxoplasma calibrated suspensions 138 
In each center, the same batch of Toxoplasma calibrated suspension was extracted using 139 
QIAamp DNA mini-kit® and amplified in parallel with the RA and the ELITe MGB assay.  In 140 
one center, one batch of calibrated suspension was also extracted using EXTRAblood®, with 141 
or without adding 5 µL of internal control (IC)(CPE-DNA Internal Control, Elitech®), following 142 
the manufacturer’s instructions. Briefly, 200 µL of samples were mixed with 25 µL of 143 
proteinase K, 200 µL of lysis buffer, 10 µL of carrier RNA and 5 µL of IC, incubated at 70°C for 144 
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10 min, then centrifuged for 5 sec at 11,000 rpm. After addition of 210 µL of absolute 145 
ethanol and a brief centrifugation, the lysate was loaded into a column. After several 146 
washing steps, DNA was eluted in 60 µL of buffer. Quality control samples (QCMD® 2014) 147 
were also extracted using this technique. 148 
 149 
DNA amplification 150 
Reference methods 151 
The in-house methods used by the three participants targeted the rep529 sequence and has 152 
been previously evaluated and published (5, 8, 10, 14). Technical details can be found in 153 
Table 1. All three RA satisfy annual external quality control program, managed by the 154 
National Reference Center for Toxoplasmosis (Centre Hospitalier Universitaire de 155 
Montpellier). All DNA from clinical samples were re-amplified in parallel with the RA method 156 
and the ELITe MGB® assay. Newly-extracted Toxoplasma suspensions were amplified with 157 
both techniques.  158 
Toxoplasma ELITe MGB® method 159 
The Toxoplasma ELITe MGB® assay was performed according to the manufacturer’s 160 
instructions, using 10 µL of the DNA template and 20 µL of mix. When the Elitech IC was not 161 
added during extraction (calibrated suspensions or clinical samples previously extracted 162 
using the QIAamp DNA mini-kit®), 2 µL of Elitech IC was added in 10 µL of template DNA, and 163 
10 µL of this solution were used for amplification, as suggested by the manufacturer.  164 
The assay has been validated only on Applied Biosystems devices. In this study, ELITe MGB® 165 
amplification was performed using a StepOnePlus® device or ABI® Prism 7000 166 
(ThermoFisher), and the following program: 2 min at 50°C, 2 min at 94°C, and 45 cycles of 10 167 
sec at 94°C, 30 sec at 60°C and 20 sec at 72°C. Each clinical sample was analyzed in a single 168 
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reaction, as well as the QCMD® EQC DNA. If the result was not concordant with that of the 169 
previous routine diagnosis, a second PCR was performed with the Elitech® method and the 170 
in-house PCR. The LOD (95% sensitivity) announced by the manufacturer in whole blood 171 
samples is 34.29 or 88.72 T. gondii /mL, and 5.47 or 1.91 T. gondii/extraction in AF samples, 172 
using manual extraction (EXTRAblood®, Elitech) or automated extraction (NucliSENS 173 
EasyMAG®, BioMérieux), respectively. 174 
Performance score 175 
For each technique, a performance score was calculated from the results obtained with 176 
calibrated suspensions, as follows: number of positive replicates/total number of 177 
amplifications.  178 
 179 
Statistical analysis 180 
The Mann-Whitney test was used to compare the mean Ct obtained with qPCR assays for 181 
the calibrated Toxoplasma suspensions. When the number of positive replicates was below 182 
three, a two-way ANOVA analysis was used instead.  183 
For clinical samples, the analysis of qualitative results obtained with both techniques was 184 
analyzed using a Chi-square test or a Fisher’s exact test.  185 
Statistical analysis was made using GraphPad® Prism V5 (GraphPad software, USA). P < 0.05 186 
was considered significant. 187 
 188 
RESULTS 189 
Comparative testing using Toxoplasma calibrated suspensions 190 
The first step of the study was to determine the PCR performance scores using serial 191 
dilutions of calibrated Toxoplasma DNA suspension. PCR performance scores were 192 
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calculated as described elsewhere (7, 15), using the T. gondii (Tg) DNA serial dilution assay, 193 
and are reported in Table 2. In all three centers, the scores obtained using the in-house 194 
method and the Elitech® assay were close, but the RA method had a higher score than the 195 
commercial assay in two out of three centers (p<0.01, Table 2). Taken together, the lowest 196 
parasite concentrations, i.e. “1” and “0.1” Toxoplasma/mL, were inconstantly amplified. For 197 
“1 T.g./mL, the difference was statistically significant (5 positive out of 10 replicates and  8 198 
out of 10 replicates with ELITe MGB and RAs, respectively)(p<0.01). 199 
The mean cycle threshold (Ct) of amplification obtained with Toxoplasma ELITe MGB® was 200 
calculated for concentrations of calibrated suspensions between 1 and 10,000 Tg/mL, and 201 
the results were compared for the two DNA extraction methods. Surprisingly, the mean Cts 202 
obtained with the combination EXTRAblood®/Elite MGB® (recommended by the 203 
manufacturer) were significantly higher than those obtained with the combination QIAamp 204 
®/Elite MGB® (29.2±0.17 versus 27.8±0.18, p<0.05 for 100 Tg/mL and 39.3±0.07 versus 205 
34.6±0.4, p<0.001 for 1 Tg/mL) (Figure 1).  206 
 207 
Comparative testing using clinical samples 208 
When using clinical samples, the concordance between the in-house method and the Elite 209 
MGB® assay was 92% (118/128). All negative DNAs were tested negative (33/33); but false 210 
negative results were obtained using the Elite MGB® kit as compared with the RAs for 10 out 211 
of 95 positive samples, yielding a specificity of 100% and a relative sensitivity of 89.5% for 212 
the kit. This sensitivity was 100% for AF (38/38) and other fluid samples (AH, CSF), but only 213 
79% (34/43) for placenta and 80% (4/5) for buffy coat samples (Table 3). In 9/10 cases, the 214 
false negative results were obtained for placenta samples with high Ct values (>37). To rule 215 
out PCR inhibition, samples were diluted to 1/10th and re-tested. Additionally, as the nature 216 
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of the Elitech® IC was not known and could be suspected to interfere with small amounts of 217 
parasite DNA, these false negative samples were also tested without IC. Amplification was 218 
restored from plain DNA in the absence of IC (2 cases, with Ct of 39.7 and 40.7) and after 219 
dilution to 1/10th and absence of IC in one case (Ct = 36.7). No amplification was observed 220 
after dilution to 1/10th when IC was not removed. 221 
Overall, the sensitivity for fluid samples was higher than for cellular samples (100% versus 222 
80%, p<0.01)(Table 3).  223 
Finally, the qualitative results obtained using the QCMD® 2014 quality control samples were 224 
concordant for the RA1 and Elite MGB® assays (7/7 positive samples and 3/3 negative 225 
samples; Table 3). Mean Cts obtained with both techniques were not statistically different 226 
(p=0.8, data not shown).   227 
 228 
Influence of IC on amplification performances 229 
As the observation above suggested a competing effect of the IC, another series of DNA 230 
extractions of a calibrated Toxoplasma suspension using different conditions was launched 231 
to confirm this hypothesis. It appeared that DNA extraction with EXTRAblood® (with 5 µL of 232 
IC added in the sample as recommended) followed by amplification with Elite MGB® 233 
performed as well as extraction with EXTRAblood® followed by addition of IC at the time of 234 
amplification with ELITe MGB® (Figure 2A). Surprisingly, at the “1 Tg/mL” concentration, the 235 
mean Ct was significantly lower when the IC was withdrawn from the extraction and 236 
amplification steps than that obtained after extraction with EXTRAblood® including IC (33.57 237 
±0.93 versus 38.75 ±1.18, p<0.001) (Figure 2A). Similarly, the addition of the IC to the mix of 238 
amplification also led to an increase of the mean Ct at the “1 Tg/mL” concentration (33.57 239 
±0.93 versus 37.97 ±0.007, p<0.001). In another experiment, both extraction methods 240 
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(QIAamp DNA mini-kit® and EXTRAblood®) were compared using the same amplification 241 
method (RA1). Whatever the parasite concentration, Ct values were much lower when DNA 242 
was extracted with the QIAamp DNA mini-kit® than with EXTRAblood® (36.62 ± 1.38 versus 243 
45, and 21.52 ±0.08 versus 25.35 ±0.2, for the lowest and highest parasite concentrations, 244 
respectively; p<0. 001) (Figure 2B).  245 
 246 
DISCUSSION  247 
In the diagnosis of congenital toxoplasmosis, a high sensitivity of the PCR assay is needed, as 248 
parasite loads in amniotic fluids from congenitally infected infants are frequently as low as 249 
10 tachyzoites/mL or less (16). Early treatment of pregnant women who benefit from 250 
serological screening in France, could account for such low parasite loads (17). High 251 
performance of molecular assays is also a key issue in immunocompromised patients, for 252 
whom rapid and accurate diagnosis is essential. Furthermore, toxoplasmosis is of increasing 253 
importance in HIV-negative immunocompromised patients, due to the growing number of 254 
transplantations and to the use of immunosuppressive drugs for the treatment of chronic 255 
inflammatory diseases (6).  Here, when applied to calibrated DNA samples, the Toxoplasma 256 
ELITe MGB® assay showed similar performance as the three laboratory-developed reference 257 
methods down to 10 T.g/mL, but the lowest concentrations were inconstantly detected 258 
(Table 2), despite a higher DNA input into the amplification reaction (10 µL) than in the 259 
reference methods (Table 1). 260 
When using clinical samples, the Toxoplasma ELITe MGB® assay showed a 100% sensitivity 261 
for amniotic fluids, and yielded congruent results on a batch of external quality controls 262 
(QCMD® 2014).  Although the kit is commercialized, i.e. validated, only for amniotic fluids 263 
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and whole blood samples, we included other sample types which are frequently sent to 264 
laboratories for diagnosis, such as aqueous humor or CSF. We also included placenta 265 
samples, which offer the advantage to mimic blood samples and to be linked to a clinical 266 
history and follow-up of neonates, thus can be definitely classified as true-positive or not. 267 
The sensitivity for other fluid samples was as good as for AF, although the number of 268 
samples included was small. However, the sensitivity was much lower for other sample 269 
types, in particular placenta samples. These results show that this commercial assay 270 
performs better on samples with low cellularity or reduced contamination with red blood 271 
cells, which confirms the lower sensitivity using whole blood, reported by the manufacturer 272 
himself. As routinely done in the three reference laboratories, when a PCR inhibition is 273 
suspected from the observation of high Ct values with their IC, samples were re-tested after 274 
sample dilution. This strategy was thus applied to the false-negative samples obtained with 275 
the ELITe MGB assay, but it didn’t fit for amplification restoration. Additionally, as the nature 276 
of the Elitech® IC was not known and could be suspected to interfere with small amounts of 277 
parasite DNA, these false-negative samples were also tested without IC. This allowed to 278 
restore Toxoplasma amplification in 30% of these samples, thus demonstrating that 279 
competition of the Elitech IC could partially explain the false negative results. The inhibitory 280 
effect of the Elitech® IC was definitely confirmed using low concentrations of Toxoplasma 281 
calibrated suspensions (Figure 2A). However, the technical instructions from the 282 
manufacturer do not mention that the reactions should be performed in duplicate, plain and 283 
diluted, or with and without IC, as this significantly augments the cost of the test. With 284 
respect to the interpretation of IC amplification, it is stated in the manufacturer’s 285 
instructions that a Ct ≤ 35 is suitable for a correct interpretation of results. During our 286 
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assays, the Ct obtained for IC was always < 30, thus it could be reasonably considered that 287 
the test was valid; yet false negative results have been found.  288 
As the DNA extraction method is also known to influence the performance of PCR 289 
amplification (18), we decided to compare the Ct results of calibrated parasite suspensions, 290 
extracted using either the extraction kit (EXTRAblood®) as recommended by the 291 
manufacturer, or the QIAamp DNA blood mini-kit®, as routinely done in the three labs. 292 
Subsequent amplification with the RA1 showed that the combination QIAamp® 293 
extraction/RA1 performed much better than the combination EXTRAblood®/RA1 (Figure 2B), 294 
stressing the need to evaluate the extraction and PCR methods together, as emphasized 295 
earlier (19). Moreover, the combination EXTRAblood®/Elite MGB (recommended by the 296 
manufacturer) performed significantly worse than the combination QiaAmp®/Elite MGB to 297 
amplify low parasite concentrations (Figure 1), thus should be avoided. The evaluation of the 298 
combination extraction / amplification methods is of peculiar importance for off-label use of 299 
commercial PCR assays, particularly with cell-rich samples types, as its efficiency is 300 
determining to detect very low parasite amounts. Furthermore, the validation of the entire 301 
process is necessary to meet the requirements of quality assurance system. 302 
Regarding the handiness and good laboratory practices, the mix provided in the kit contains 303 
uracil-N-glycosylase (UNG) to limit carryover contaminations from previously amplified PCR 304 
products. The kit does not include a standard to perform a curve to quantify parasite loads. 305 
The PCR assay, the internal control and the positive control are purchased in three separate 306 
vials, thus the management of batch traceability is not easy. 307 
Several qPCR commercial assays are available to date to detect Toxoplasma DNA, but very 308 
few have been evaluated using clinical samples or in routine use. A previous multicenter 309 
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study conducted by the Molecular Biology Group of the French NRCT evaluated another 310 
commercial kit by Bio-Evolution® using 157 amniotic fluid samples, and found a 99% 311 
concordance for T. gondii-infected samples (13). In the present study, we enrolled a smaller 312 
amount of amniotic fluid samples (56), but the Toxoplasma ELITe MGB® assay showed also a 313 
good concordance using these samples.  314 
Taken together, this study showed that the Toxoplasma ELITe MGB® assay appears suitable 315 
for prenatal diagnosis. However, a note of caution is in order when using cell-rich or 316 
hemoglobin-rich samples, as this carries the risk of false negative results. In our hands, the 317 
use of the EXTRAblood® DNA extraction lowered the performance of the Toxoplasma ELITe 318 
MGB® assay for low parasite concentrations, and dramatically lowered the sensitivity of the 319 
in-house PCR method tested. Like for all molecular diagnostic methods, clinical 320 
microbiologists who would aim at implementing this technique in their laboratory should 321 
evaluate the combination of extraction and amplification methods before changing one or 322 
the other. 323 
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 LEGENDS TO FIGURES 410 
Figure 1: Evaluation of the Toxoplasma Elite MGB® kit using serial dilutions of Toxoplasma 411 
calibrated suspensions. Calibrated suspensions were extracted using either QIAamp DNA 412 
mini-kit® or Extrablood®, before being amplified using Toxoplasma Elite MGB®. 413 
Amplifications were performed in triplicate. Data are expressed as means ± SEM; *, p<0.05, 414 
***, p<0.001.  415 
 416 
Figure 2: Evaluation of the impact of the internal control (IC) and of the extraction method 417 
on amplification efficacy. (A) Comparison of the Ct of amplification obtained with Elite MGB® 418 
PCR on DNA extracted with EXTRAblood®, with addition of internal control (+IC) in the 419 
sample before extraction, or without internal control (-IC), or after addition of IC in DNA at 420 
the time of amplification; (B) Comparison of the Ct obtained with the reference assay 1 421 
(RA1) after DNA extraction with EXTRAblood® or with QIAamp DNA mini-kit®. Amplifications 422 
were performed in triplicate; data are expressed as means ± SEM; **, p<0.01, ***, p<0.001. 423 
 424 
 425 
 426 
 427 
  428 
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Table 1: Technical description of the four PCR methods used 429 
 430 
Technique  DNA 
target 
Type of probe DNA 
input (µL) 
Internal control No of 
cycles 
PCR device 
RA1 rep529 Taqman 
(FAM-TAMRA) 
5 Universal extraction & 
inhibition DNA control 
(Diagenode®) 
40 StepOnePlus® 
(ThermoFisher) 
RA2 rep529 Taqman 
 
5 non-competitive exo-
genous DNA inserted in 
PCR 2.1 vector 
50 AB7000® 
(ThermoFisher) 
RA3 rep529 FRET 
 
7 PhiX (DNA 
Bacteriophage) 
40 LC2.0® 
(ThermoFisher) 
Toxoplasma 
Elite MGB® 
rep529 Taqman  
(FAM-MGB) 
10 Artificial DNA sequence 45 StepOnePlus® 
(ThermoFisher) 
RA: reference assay 431 
 432 
  433 
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Table 2: Performance scores (No of positive reactions/No of reactions performed) for the 434 
four PCR assays using DNA serial dilutions of a calibrated Toxoplasma suspension 435 
 436 
Concentration Lab 1 Lab 2 Lab 3
RA1 
(Qiagen) 
Elite MGB 
(Qiagen) 
Elite MGB
(Extrablood+IC) 
RA2
(Qiagen) 
Elite MGB 
(Qiagen) 
RA3 
(Qiagen) 
Elite MGB 
(Qiagen) 
10,000 Tg/mL  3/3 3/3 3/3 3/3 3/3 4/4 4/4 
1,000 Tg/mL 3/3 3/3 3/3 3/3 3/3 4/4 4/4
100 Tg/mL 3/3 3/3 3/3 3/3 3/3 4/4 4/4 
10 Tg/mL 3/3 3/3 3/3 3/3 3/3 4/4 4/4
1 Tg/mL 3/3 2/3 2/3 1/3 0/3 4/4 3/4 
0.1 Tg/mL 0/3 0/3 0/3 0/3 1/3 1/4 1/4
PCR 
performance 
score (%) 
15/18* 
(83.3) 
14/18 
(77.8) 
14/18
(77.8) 
13/18
(72.2) 
13/18
(72.2) 
21/24* 
(87.5) 
20/24
(83.3) 
Tg, Toxoplasma gondii; RA, reference assay 437 
*p<0.01, compared to Elite MGB/Qiagen 438 
 439 
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Table 3: Performances of the Toxoplasma ELITe MGB® assay using clinical samples, 440 
according to the sample type 441 
 442 
 443 
Sample type  Sensitivity 
% (n/N) 
Specificity 
% (n/N) 
Clinical samples (n = 128) 89.5 (85/95) 100 (33/33) 
    Amniotic fluid (n = 56) 100 (38/38) 100 (18/18) 
    Other fluidsa (n = 9) 100 (7/7) 100 (2/2) 
    Placenta (n = 55) 79 (34/43) 100 (12/12) 
    Blood (buffy coat) (n = 6) 80 (4/5) 100 (1/1) 
    Biopsies (n = 2) 100 (2/2) na 
QCMD® samples (n = 10) 100 (7/7) 100% (3/3) 
a consisting in 5 cerebrospinal fluid and 4 aqueous humor samples 444 
na, not applicable 445 
10000 1000 100 10 1
0
10
20
30
40
50
Qiagen/ Elite MGB
Extrablood+IC / Elite MGB
*
***
Toxoplasma concentrations /mL
C
t
10000 1000 100 10 1
0
10
20
30
40
50
Extrablood (+IC) /Elite MGB
Extrablood (-IC) /Elite MGB
Extrablood (-IC) /Elite MGB (+IC)
***
***
Toxoplasma concentration /mL
C
t
10 000 1 000 100 10 1
0
10
20
30
40
50
Qiagen/ RA1
Extrablood/ RA1
***
**
**
**
***
Toxoplasma concentration /mL
C
t
A 
B 
